BI-3406
$350.00
CAS No.: 2230836-55-0
Catalog No.: 193441
Purity: 95%
MF: C23H25F3N4O3
MW: 462.472
Storage: 2-8 degree Celsius
SMILES: NC=1C=C(C=C(C1)C(F)(F)F)[C@@H](C)NC1=NC(=NC2=CC(=C(C=C12)O[C@@H]1COCC1)OC)C
Catalog No.: 193441
Purity: 95%
MF: C23H25F3N4O3
MW: 462.472
Storage: 2-8 degree Celsius
SMILES: NC=1C=C(C=C(C1)C(F)(F)F)[C@@H](C)NC1=NC(=NC2=CC(=C(C=C12)O[C@@H]1COCC1)OC)C
BI-3406; N-((R)-1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-7-methoxy-2-methyl-6-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-4-amine; CAS No.: 2230836-55-0; BI-3406. PROPERTIES: BI-3406 is a white to pale yellow crystalline solid with the molecular formula C25H25N5O5. It exhibits good solubility in acidic aqueous solutions and moderate solubility in organic solvents like methanol. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using gloves to prevent skin contact, and ensuring eye protection. With a molecular weight of approximately 495.50 g/mol, it demonstrates moderate plasma protein binding and a half-life suitable for once-daily dosing regimens. The compound has a calculated logP around 1.8, contributing to its pharmacokinetic profile. Its melting point ranges between 160-165 C, and it forms stable salt formulations that enhance bioavailability. APPLICATIONS: BI-3406 serves as a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor agonist, investigated for anticancer therapy. In preclinical studies, it is used to evaluate apoptosis induction in various cancer cell lines and to study synergistic effects with chemotherapeutic agents. The compound is employed in combination therapy research to enhance tumor cell killing and overcome resistance mechanisms. Additionally, it functions as a research tool in cell death signaling pathways to understand the molecular basis of TRAIL-mediated apoptosis. According to "Apoptosis-Inducing Agents in Cancer Therapy," BI-3406 represents a promising approach to selectively target cancer cells while sparing normal tissues.
Reviews
Write Your Own Review